Top Markets
#1 Black Phoenix Black Phoenix +166.18%
#2 Islamic Coin Islamic Coin +158.21%
#3 Glidr Glidr +58.56%
#4 Cryptopia Cryptopia +20.80%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.53%
#6 MarsCoin MarsCoin +13.34%
#7 Test Test +12.58%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +11.52%
#9 Palladium Network Palladium Network +9.76%
#10 Useless Coin Useless Coin +9.21%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Kedudukan dalam Saham #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Harga Saham
$0.0005
Disegerakkan terakhir: 2026-08-11
Modal Pasaran
$10.28K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan VIA Pharmaceuticals, Inc. (VIAP)

Kategori

Healthcare
Margin Operasi untuk VIA Pharmaceuticals, Inc. (VIAP)
Margin Operasi pada 2026 TTM: 0.00%
Menurut laporan kewangan dan harga saham terkini VIA Pharmaceuticals, Inc., margin operasi semasa (TTM) ialah 0.00%. Pada akhir 2026, margin operasi syarikat ialah 0.00%.
Sejarah Margin Operasi untuk VIA Pharmaceuticals, Inc. dari 2026 hingga 2026
Margin Operasi pada akhir setiap tahun
Tahun Margin Operasi Ubah
Tidak cukup data untuk tarikh yang disediakan.
Margin Operasi untuk syarikat serupa atau pesaing
Syarikat Margin Operasi Perbezaan Margin Operasi Negara
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
67.93% -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
0.00% -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
0.00% -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
0.00% -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
0.77% -
US
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.